Xigen S.A.
Records under this name other than patents Xigen S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,006,185 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,150,618 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,180,159 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,981,052 | Novel JNK Inhibitor Molecules Formerly held In force · High confidence | In force | High confidence | |
| US 9,290,538 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Formerly held Term ended Term ended Sep 12, 2026 · High confidence | Term ended | Term ended Sep 12, 2026 | High confidence |
| US 10,023,615 | Efficient Transport into White Blood Cells Formerly held Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 8,748,395 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Lapsed on the fee record Ended Jun 10, 2026 · High confidence | Lapsed on the fee record | Ended Jun 10, 2026 | High confidence |
| US 8,236,924 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway Term ended Term ended Feb 27, 2026 · From the USPTO record | Term ended | Term ended Feb 27, 2026 | From the USPTO record |
| US 8,080,517 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway Formerly held Term ended Term ended Sep 12, 2025 · High confidence | Term ended | Term ended Sep 12, 2025 | High confidence |
| US 9,624,267 | JNK inhibitor molecules Formerly held Lapsed on the fee record Ended Apr 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 18, 2025 | From the USPTO record |